UBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978

UBS analyst Trung Huynh has upgraded Regeneron Pharmaceuticals (NASDAQ: REGN) from Neutral to Buy. The price target for the stock has been raised significantly from $660 to $978.